Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Rutgers: $2.2M Grant Supports Exploration of Combined Therapies that Target Cancer Pathways and Promote Cell Death

7/15/2016

0 Comments

 
New Brunswick, NJ ― The director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey, Janice M. Mehnert, MD, is a co-principal investigator on a $2,271,427 grant (R01CA193970-01A1) recently awarded by the National Cancer Institute (NCI). 
 
Dr. Mehnert is collaborating with researcher Ryan J. Sullivan, MD, at Massachusetts General Hospital Cancer Center to improve upon available cancer therapies that aim to block specific pathways that promote tumor growth.
 
When compared to chemotherapy, anti-cancer therapies designed to block the BRAF and MEK pathways that are known for promoting tumor growth improve response rate, progression free survival and overall survival in more than 50 percent of patients with BRAF-mutant melanoma that has spread to other parts of the body.
 
While these drugs have become standards of care, patients still experience disease progression and die of their disease.  Drs. Mehnert and Sullivan and colleagues aim to improve the effectiveness of BRAF-directed therapy by targeting the death of cancer cells.
​The pair previously demonstrated that treatment with the BRAF-directed therapy vemurafenib or a combination of the drugs dabrafenib and trametinib increases a certain protein in melanoma cell lines associated with cell death, or apoptosis.
 
Pre-clinical data from the group found that when an investigational agent known as navitoclax, which promotes apoptosis, is combined with these drugs, there is an increase in tumor regression and cell death. 
 
To further study the safety and efficacy of these combined therapies, Mehnert and Sullivan opened a clinical trial sponsored by the NCI’s Cancer Therapy Evaluation Program at both Rutgers Cancer Institute and Dana-Farber Harvard Cancer Center.
 
The grant will support the evaluation of results from the trial. Investigators also will explore biomarkers that predict the outcome of the combination of navitoclax with dabrafenib and trametinib. Employing genomic sequencing analysis of tumors from pre-clinical models also will be part of the work.
 
“We anticipate our research will determine an ideal strategy for implementing a new therapeutic, precision medicine approach to improve clinical outcomes of patients with BRAF-mutant melanoma and potentially other BRAF-mutant solid tumors,” notes Mehnert, who is also an associate professor of medicine at Rutgers Robert Wood Johnson Medical School.
 
The project period runs through 2020.
 
About Rutgers Cancer Institute of New Jersey
 
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, the Cancer Institute of New Jersey is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention.  Physician-scientists at Rutgers Cancer Institute engage in translational research, transforming their laboratory discoveries into clinical practice. 
 
To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving. Follow us on Facebook at www.facebook.com/TheCINJ.
 
The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Affiliate Hospitals: JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), and Robert Wood Johnson University Hospital Somerset.
 
 
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
222 West State Street
Suite 302
Trenton, NJ 08608
732-729-9619